| Dr R Douglas Quay, OD | |
|
2030 W Tilghman St Ste 101, Allentown, PA 18104-4354 | |
| (610) 432-3258 | |
| (610) 289-2100 |
| Full Name | Dr R Douglas Quay |
|---|---|
| Gender | Male |
| Speciality | Optometrist |
| Location | 2030 W Tilghman St Ste 101, Allentown, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467547570 | NPI | - | NPPES |
| 0003330 | Other | PA | AETNA PIN# |
| 51971 | Other | PA | DAVIS VISION |
| 01395401 | Other | PA | BLUE CROSS |
| 0201390001 | Other | PA | MEDICARE DMERC |
| OE-T008757 | Other | PA | LICENSE NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | OE-T008757 (Pennsylvania) | Primary |
| Provider Name | Tony H Sankari |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1093802746 PECOS PAC ID: 4486654076 Enrollment ID: I20080610000046 |
News Archive
Abraxis BioScience, Inc., a fully integrated biotechnology company, welcomes the announcement today that following a full submission, the Scottish Medicines Consortium (SMC) has accepted ABRAXANE® (paclitaxel albumin) for restricted use within the National Health Service (NHS) for Scotland in patients who would otherwise receive docetaxel or 3-weekly solvent-based paclitaxel as second-line treatment for metastatic breast cancer.
BioAlliance Pharma SA, a Company dedicated to orphan oncology products and specialty products, today announces the initiation of ReLive, its phase III clinical trial with Livatag(doxorubicin Transdrug), as scheduled in the advancement calendar of the project.
A new analysis from amfAR, The Foundation for AIDS Research, "estimates potential human impacts of funding changes [in global health programs] proposed in the President's fiscal year 2013 budget request when compared to current operating budget levels (fiscal year 2012)."
A new genomic test combining multiple signatures - a patient's estrogen receptor status, endocrine therapy response, chemotherapy resistance and sensitivity - shows promise as a predictor of chemotherapy response and survival benefit in women with invasive breast cancer, according to research led by The University of Texas MD Anderson Cancer Center.
100 000 deaths and 6 million years of healthy life lost (or DALYs) ever year, in children and adolescents from birth to 19 years of age, are caused by outdoor and indoor air pollution, unsafe water, lead and injuries.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr R Douglas Quay, OD 2030 W Tilghman St Ste 101, Allentown, PA 18104-4354 Ph: (610) 432-3258 | Dr R Douglas Quay, OD 2030 W Tilghman St Ste 101, Allentown, PA 18104-4354 Ph: (610) 432-3258 |
News Archive
Abraxis BioScience, Inc., a fully integrated biotechnology company, welcomes the announcement today that following a full submission, the Scottish Medicines Consortium (SMC) has accepted ABRAXANE® (paclitaxel albumin) for restricted use within the National Health Service (NHS) for Scotland in patients who would otherwise receive docetaxel or 3-weekly solvent-based paclitaxel as second-line treatment for metastatic breast cancer.
BioAlliance Pharma SA, a Company dedicated to orphan oncology products and specialty products, today announces the initiation of ReLive, its phase III clinical trial with Livatag(doxorubicin Transdrug), as scheduled in the advancement calendar of the project.
A new analysis from amfAR, The Foundation for AIDS Research, "estimates potential human impacts of funding changes [in global health programs] proposed in the President's fiscal year 2013 budget request when compared to current operating budget levels (fiscal year 2012)."
A new genomic test combining multiple signatures - a patient's estrogen receptor status, endocrine therapy response, chemotherapy resistance and sensitivity - shows promise as a predictor of chemotherapy response and survival benefit in women with invasive breast cancer, according to research led by The University of Texas MD Anderson Cancer Center.
100 000 deaths and 6 million years of healthy life lost (or DALYs) ever year, in children and adolescents from birth to 19 years of age, are caused by outdoor and indoor air pollution, unsafe water, lead and injuries.
› Verified 5 days ago
Lehigh Valley Eye Care Associates Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2030 W Tilghman St, Suite 101, Allentown, PA 18104 Phone: 610-432-3258 Fax: 610-289-2100 | |
Marc M Berson, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2804 Walbert Ave, Allentown, PA 18104 Phone: 610-439-3937 Fax: 610-439-0215 | |
Shepherd Hills Eye Care Center Optometrist Medicare: Medicare Enrolled Practice Location: 5940 Hamilton Blvd, Suite C, Allentown, PA 18106 Phone: 610-481-9200 Fax: 610-481-0289 | |
Kirti Patel, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 4620 Broadway, Allentown, PA 18104 Phone: 610-841-7990 | |
Jenna Juarez, Optometrist Medicare: Medicare Enrolled Practice Location: 101 N 6th St Ste 300, Allentown, PA 18101 Phone: 484-224-0775 | |
Radoslav Ivanov, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 401 N 17th St, Suite 103, Allentown, PA 18104 Phone: 610-969-3070 Fax: 610-969-3073 | |
Tony H Sankari, OD Optometrist Medicare: May Accept Medicare Assignments Practice Location: 2030 W Tilghman St, Suite 101, Allentown, PA 18104 Phone: 610-432-3258 Fax: 610-289-2100 |